+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 249 Actively Recruiting clinical trials

C

Actively Recruiting

Researchers are evaluating treatments for patients with high-risk pulmonary embolism PE, a serious condition that requires immediate clot removal in addition to blood thinners. This trial compares two approaches catheter-directed thrombectomy CDT, a procedure that directly removes clots using a device, versus standard full-dose systemic thrombolysis, which dissolves clots using medication. The study aims to see if CDT can reduce death rates and serious complications better than the usual treatment, while also improving recovery and quality of life over one year. Participants are randomly assigned to one of two groups. One group receives the CDT procedure, where a catheter is guided through veins to the lungs to extract clots using suction, combined with blood thinners during the procedure. The other group receives full-dose systemic thrombolysis using clot-dissolving drugs such as Alteplase, Urokinase, or Tenecteplase. The study is open-label, meaning both patients and doctors know which treatment is given. Researchers will monitor effects at various points, including day 7, day 30, and up to one year after treatment. During the trial, participants undergo evaluations including clinical and hemodynamic assessments to determine treatment success, monitoring of oxygen levels, length of stay in intensive care and hospital, and quality of life questionnaires over a year. The main measure is a combined rate of death, treatment failure, major bleeding, and stroke at 30 days. Secondary outcomes include survival, bleeding events, oxygen use, and long-term functional recovery. Cost-effectiveness of the treatments will also be analyzed after one year.

Age: 18Years +All GendersPhase Not Applicable
1 location
S

Actively Recruiting

Researchers are studying a new type of scan called FAPI-PETCT to see how well it detects metastases in patients with advanced gastric cancer. The study aims to find out if this scan can better identify cancer spread, leading to changes in treatment plans such as avoiding unnecessary surgeries or shifting to comfort-focused care. It also evaluates whether the scan causes less burden for patients compared to current methods. Participants will receive the standard care for gastric cancer and undergo one additional FAPI-PETCT scan, where a small amount of 18F-FAPI-74 is given intravenously about 60 minutes before a PETCT scan lasting around 20 minutes. The results from this scan will help doctors decide on further tests or surgery needed. The study monitors changes in diagnosis and treatment decisions based on the scan. During the study, participants will complete questionnaires taking about 4 hours total and spend approximately 2 hours for the extra scan. Researchers will measure outcomes such as changes in treatment intent, diagnostic work-up, scan accuracy, incidental findings, patient burden, quality of life, and safety over about one year. Follow-up includes quality of life assessments and cost evaluations at multiple time points after staging.

Age: 18Years +All GendersPhase 2Phase 3
10 locations
S

Actively Recruiting

Researchers are evaluating new treatment options for people with locally advanced, unresected non-small cell lung cancer NSCLC that has a KRAS G12C gene mutation. This trial aims to learn if combining calderasib MK-1084 with durvalumab, an immunotherapy, after chemotherapy and radiation can help patients live longer without their cancer growing or spreading. Participants will be randomly assigned to receive either calderasib along with durvalumab or a placebo with durvalumab. Calderasib is taken as an oral tablet, while durvalumab is given by intravenous infusion. The study is blinded so neither participants nor researchers know who receives the active drug or placebo during treatment. During the study, participants will be monitored regularly to assess cancer progression, survival, quality of life, and side effects. This includes tumor testing, blood work, and questionnaires over up to approximately 6 years for progression-free survival and up to 9 years for overall survival and other health measures. The study is sponsored by Merck Sharp & Dohme LLC and follows participants from screening through long-term follow-up.

Age: 18Years +All GendersPhase 3
107 locations
M

Actively Recruiting

Researchers are conducting a master protocol trial designed to efficiently study several different drugs for children and young adults with various types of cancer. This approach allows multiple clinical trials under one common research plan, with each trial focusing on specific cancers like desmoplastic small round cell tumor, synovial sarcoma, and Ewings sarcoma. New drug studies may be added over time as new treatments emerge. Participation depends on how long the treatment benefits last. The study evaluates combinations of drugs given in cycles, including intravenous and oral medicines such as ramucirumab, cyclophosphamide, vinorelbine, gemcitabine, docetaxel, abemaciclib, irinotecan, and temozolomide. Different treatment groups receive specific drug combinations tailored to the cancer type, with treatment cycles lasting 21 or 28 days depending on the regimen. Each group is randomized to receive either an experimental drug combination or an active comparator without any blinding. Participants will be involved from screening through treatment and monitored regularly. Researchers will assess how many participants are assigned to each specific intervention plan within the first four weeks and track treatment effects. Participants must have measurable or evaluable disease, adequate organ function, and meet performance status criteria. Female participants of childbearing potential undergo pregnancy testing and must use contraception during and after treatment. Safety, adherence, and side effects are carefully monitored throughout the study, which is expected to continue until 2027.

Age: 1Year - 39YearsAll GendersPhase 2
72 locations
C

Actively Recruiting

Researchers are evaluating two different weekly doses of Alpha1-Proteinase Inhibitor Alpha1-PI given by injection under the skin compared with the standard intravenous doses in adults with Alpha-1 Antitrypsin Deficiency. This Phase 3, open-label study aims to understand how the body processes the medicine and to assess the safety and tolerability of the different doses. Participants are randomly assigned to treatment groups in a parallel design, with both doctors and participants aware of the assigned treatment. Participants undergo two treatment periods the first with intravenous IV Liquid Alpha1-PI given weekly at either 60 mgkg or 120 mgkg for 8 weeks, followed by a second period with subcutaneous SC Alpha1-PI 15% injection at corresponding higher doses 90 mgkg or 180 mgkg also given weekly for 8 weeks. Participants receive each dosing schedule sequentially to compare pharmacokinetics and safety between IV and SC administration. During the study, participants have regular visits to monitor steady-state levels of Alpha1-PI in the blood, lung function tests, and safety assessments. Key measurements include the area under the curve AUC of Alpha1-PI over each weekly interval and trough serum levels at specific weeks. The study includes screening, 16 weeks of treatment divided into two 8-week periods, and ongoing safety and tolerability evaluations throughout.

Age: 18Years - 80YearsAll GendersPhase 3
22 locations
G

Actively Recruiting

This trial evaluates the safety and effectiveness of intravenous AOC 1044, also known as delpacibart zotadirsen, in treating boys aged 7 to 16 years with Duchenne Muscular Dystrophy DMD who have gene mutations that can be targeted by exon 44 skipping. The study is a phase 3, randomized, double-blind, placebo-controlled trial with a parallel design. It aims to assess how this treatment impacts physical abilities related to muscle function. Participants will be randomly assigned to receive either AOC 1044 or a placebo through intravenous infusion every 6 weeks for 54 weeks, totaling 9 doses during the double-blind treatment period. After this, all participants have the option to join a 54-week open-label extension, where everyone receives AOC 1044 infusions every 6 weeks for another 9 doses. The study concludes with assessments at week 108 and a safety follow-up at week 114. An independent committee will regularly review safety and efficacy data. During the study, participants will undergo various assessments including tests of muscle strength and function such as time to rise velocity, stair climb, and walkingrunning speed. Quality of life and global impression scores from both patients and caregivers will also be measured. Safety will be closely monitored throughout, with a total participation time of over two years, including the screening, treatment, extension, and follow-up periods.

Age: 7Years - 16YearsMALEPhase 3
18 locations
C

Actively Recruiting

Researchers are evaluating the effectiveness of intravenous brincidofovir IV BCV compared to intravenous cidofovir IV CDV in adults and children who have undergone allogeneic hematopoietic cell transplantation allo-HCT and have adenovirus viremia. This Phase 3, multi-center, randomized, open-label study aims to determine which treatment better clears adenovirus in this high-risk population, following guidelines that recommend weekly monitoring of adenovirus levels. Participants will be randomly assigned to receive either IV BCV or IV CDV. Treatment will continue until adenovirus DNA is undetectable in plasma for two consecutive tests one week apart or for a maximum of 12 weeks, whichever happens first. Subjects who achieve virus clearance but later experience recurrence may be retreated with their originally assigned drug, but no crossover between drugs is allowed. Safety data will be reviewed regularly by an independent monitoring board, and an adjudication committee will evaluate clinical responses. Participants will be assessed weekly through the treatment period and followed for a total of 24 weeks after randomization. Key evaluations include virologic response at Week 5 Day 1 and continued monitoring at test of cure four weeks after last dose, and at Weeks 12 and 24. Blood samples for drug concentrations will be collected, and all visits and assessments must be completed regardless of treatment duration to monitor efficacy and safety throughout the study.

Age: 2Months +All GendersPhase 3
81 locations
S

Actively Recruiting

This research aims to evaluate the effectiveness, safety, and tolerability of combining baxdrostat with dapagliflozin compared to dapagliflozin alone in people with chronic kidney disease CKD and high blood pressure. The goal is to reduce the risk of serious kidney problems, heart failure events, or cardiovascular death. This is a phase III, international, multicenter, randomized, double-blind, placebo-controlled, event-driven study focused on treatment outcomes. Participants who do not already use SGLT2 inhibitors will first undergo a 4-week dapagliflozin run-in period. After that, they will be randomly assigned to receive either baxdrostat plus dapagliflozin or placebo plus dapagliflozin. Baxdrostat dosing may start low and be increased if needed. Study visits will occur frequently early on at 2, 4, 8, 16, 34, and 52 weeks post-randomization, then approximately every 4 months. The study will end when a predetermined number of kidney or cardiovascular events occur. During the study, participants will have scheduled visits for assessments including kidney function, heart health, and safety monitoring. If they stop the study treatment early, they will continue on dapagliflozin alone and remain in the trial for follow-up visits. Researchers will measure outcomes such as sustained kidney function decline, kidney failure, heart failure events, cardiovascular death, and all-cause death over up to 37 months. Data collection continues until the study closes, with safety and tolerability closely observed throughout.

Age: 18Years +All GendersPhase 3
771 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of rilvegostomig combined with fluoropyrimidine and trastuzumab deruxtecan T-DXd compared to trastuzumab, chemotherapy, and pembrolizumab in participants with HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 combined positive score CPS of 1 or higher. This Phase 3, randomized, open-label study also includes a separate group receiving rilvegostomig with trastuzumab and chemotherapy to understand the contribution of each treatment component. The study is being conducted globally across many sites in about 25 countries. Participants are assigned to one of three treatment groups Arm A receives rilvegostomig, fluoropyrimidine capecitabine or 5-fluorouracil, and trastuzumab deruxtecan Arm B receives pembrolizumab, trastuzumab, and chemotherapy 5-fluorouracil plus cisplatin or capecitabine plus oxaliplatin Arm C receives rilvegostomig, trastuzumab, and chemotherapy. Treatments are administered mainly through intravenous infusions every three weeks, with capecitabine taken orally twice daily. The study aims to assess the role of each treatment combination over time. During the study, participants will undergo regular assessments including tumor measurements, safety checks for adverse events, and blood tests to monitor drug levels and immune responses. Researchers will track progression-free survival and overall survival for up to six years, along with response rates and treatment side effects. The study includes ongoing monitoring for eating difficulties and side-effect impact. Participants will be followed closely throughout treatment and for years afterward to evaluate long-term outcomes and safety.

Age: 18Years +All GendersPhase 3
304 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of new combinations of treatments, including novel drugs and standard therapies, for patients with advanced or metastatic non-small cell lung cancer NSCLC. This multicenter, open-label study focuses on participants with stage IV NSCLC, specifically assessing combinations involving rilvegostomig with platinum-based chemotherapy and with or without ramucirumab. The study includes a sub-study with safety and dose expansion phases to identify the recommended dose and assess treatment activity. Participants with squamous and non-squamous NSCLC will receive intravenous infusions of rilvegostomig combined with standard chemotherapy drugs such as cisplatin, carboplatin, pemetrexed, paclitaxel, or nab-paclitaxel. Some participants will also receive ramucirumab as part of their treatment. The sub-study consists of a Part A safety run-in to evaluate dose levels and a Part B expansion phase to further study the treatments. Participants are randomized into different treatment arms depending on their cancer histology. During the study, participants will undergo monitoring for adverse events, dose-limiting toxicities, and tumor response over approximately 46 months. Assessments include measuring objective response, duration and time to response, disease control, progression-free survival, overall survival, and various blood drug concentration parameters. Tumor tissue samples are required for evaluation, and safety and tolerability are closely monitored throughout the treatment period.

Age: 18Years +All GendersPhase 1Phase 2
103 locations

1-10 of 249

1